What is refractory celiac disease (RCD), including its definition, types (Type 1 and Type 2), and causes of villous atrophy, including infectious and drug-induced etiologies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Refractory celiac disease (RCD) is defined as persistent or recurrent malabsorptive symptoms and villous atrophy despite strict adherence to a gluten-free diet for at least 6-12 months, as stated in the most recent guidelines 1. This condition affects approximately 1% of celiac disease patients who fail to respond to dietary treatment. RCD is classified into two types based on immunophenotypic features:

  • Type 1 RCD maintains a normal intraepithelial lymphocyte population with normal expression of surface CD3 and CD8.
  • Type 2 RCD is characterized by abnormal intraepithelial lymphocytes lacking surface CD3, CD8, and T-cell receptors while expressing intracellular CD3. Three infectious causes of villous atrophy include:
  • Giardia lamblia infection
  • Small intestinal bacterial overgrowth (SIBO)
  • Cryptosporidium infection Three medications that can cause villous atrophy include:
  • Olmesartan (an angiotensin II receptor blocker)
  • Mycophenolate mofetil (an immunosuppressant)
  • Non-steroidal anti-inflammatory drugs (NSAIDs) Patients with suspected RCD should undergo comprehensive evaluation including repeat duodenal biopsies, HLA typing, serology testing, and flow cytometry to distinguish between the two types, as management approaches differ significantly, as recommended by recent studies 1.

From the Research

Definition of Refractory Celiac Disease

Refractory celiac disease (RCD) is defined by persistent or recurrent malabsorptive symptoms and villous atrophy despite strict adherence to a gluten-free diet (GFD) for at least 6-12 months in the absence of other causes of non-responsive treated celiac disease and overt malignancy 2, 3, 4, 5, 6.

Types of Refractory Celiac Disease

  • Type 1 RCD: characterized by a normal intraepithelial lymphocyte phenotype, and usually improves after treatment with a combination of aggressive nutritional support, adherence to a GFD, and alternative pharmacological therapies 2, 3, 4, 5, 6.
  • Type 2 RCD: defined by the presence of abnormal (clonal) intraepithelial lymphocyte phenotype, and has a severe clinical presentation and a very poor prognosis 2, 3, 4, 5, 6.

Infectious Causes of Villous Atrophy

There are no specific infectious causes of villous atrophy mentioned in the provided studies. However, it is mentioned that other causes of chronic small intestinal inflammation and villous atrophy should be excluded in the diagnosis of RCD 2, 3, 4, 5, 6.

Drug Causes of Villous Atrophy

There are no specific drug causes of villous atrophy mentioned in the provided studies. However, it is mentioned that inadvertent intake of gluten should be excluded in the diagnosis of RCD 2, 3, 4, 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Refractory celiac disease: from bench to bedside.

Seminars in immunopathology, 2012

Research

Refractory coeliac disease.

Current opinion in oncology, 2013

Research

Refractory celiac disease.

Expert review of gastroenterology & hepatology, 2014

Research

Refractory celiac disease: epidemiology and clinical manifestations.

Digestive diseases (Basel, Switzerland), 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.